About Incyte
Incyte is a publicly listed company based in Wilmington (United States) founded in 1991. Small molecules are developed for cancer and skin disease treatments. It operates on a Professional Services model. The company has 2,620 employees. Incyte has completed 4 acquisitions, including Escient Pharmaceuticals, Proteome and Vega Therapeutics. Its chief executive, as recorded, is Herve Hoppenot. Its website incyte.com draws about 82 thousand monthly visits. Incyte offers products and services including Oncology Solutions and Dermatology Solutions. Its focus areas include Biotechnology and Biopharmaceuticals. Similar companies include Moderna, BeiGene and Annexon; 3 of its 3 listed similar companies have raised funding.
Company details
Incyte is engaged in the development of biopharmaceutical solutions targeting unmet medical needs. The company operates in the healthcare sector, with a focus on oncology and dermatology. Innovative treatments and therapies are developed to address complex health challenges. Partnerships and scientific excellence are emphasized to drive patient-centered solutions globally.
- Annual Revenue$5.14 B (USD)21.22as on Dec 31, 2025
- Net Profit$1.29 B (USD)3844.96as on Dec 31, 2025
- EBITDA$1.44 B (USD)747.76as on Dec 31, 2025
- Latest Funding Round$750M (USD), Post-IPO
Nov 2013
- Employee Count2,620
- Investments & AcquisitionsEscient Pharmaceuticals
& 3 more
Products & Services of Incyte
Incyte offers a comprehensive portfolio of products and services, including Oncology Solutions and Dermatology Solutions.
Innovative treatments for cancer are developed and provided.
Therapies for skin conditions are researched and offered.
Apps and channels of Incyte
its YouTube channel Incyte has 399 subscribers and 21 videos.
Videos from Incyte
The most watched videos on Incyte's YouTube channel, Incyte (399 subscribers). Click a video to play it here.
More on Incyte.
Funding Insights of Incyte
- Total Rounds 1
- Last Round Post-IPO — $750M
- First Round $750M
(Nov 2013)
All 1 funding rounds of Incyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2013 | $750M | Post-IPO | – | – | – |
People of Incyte
779 people are tracked at Incyte (460 in leadership, 8 in board & advisors, 311 in team); the tracked headcount is 2,620.
| Name | Role | Group |
|---|---|---|
Herve Hoppenot | CEO & Chairman | Leadership |
Danielle McLean | Associate Director, Principal Medical Writer | Leadership |
Dilar Mendes | Senior Director External Manufacturing QA | Leadership |
Steven Stein | EVP & Chief Medical Officer | Leadership |
Hervé Hoppenot | Chairman, President & CEO | Leadership |
Michael Morrissey | EVP & Head of Global Technical Operations | Leadership |
Brad Yuska | Director, Bioanalysis | Leadership |
Andrew Slay | Area Sales Director ~ West | Leadership |
Paul Carango | Executive Director, Patent Counsel | Leadership |
Jennifer Lofland | Senior Scientific Director, US Medical Affairs | Leadership |
Katherine Roberts | Vice President | Leadership |
Subhabrata Purakayastha | Head Of Enterprise Systems, Quality Assurance | Leadership |
John T. Cronin | Senior Director CMC Project Managment | Leadership |
Eric Hiltebeitel | Associate Vice President, Clinical Data Management At Incyte | Leadership |
Stephen Ferenchick | Associate Vice President, Corporate Counsel, Business Development And Alliance Management | Leadership |
Grégory Devie | Director, International Supply Chain | Leadership |
Tom Tray | Vice President, Chief Accounting Officer | Leadership |
Dana Walters | Associate Director, Principal Medical Writer | Leadership |
Elizabeth Cunningham | Senior Director, Clinical Research Scientist | Leadership |
John Janik | Head Of Biotherapeutics, Clinical Development | Leadership |
759 more people are available in the full profile.
Complete people profiles for Incyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Incyte
Incyte is a publicly listed company on the NASDAQ with ticker symbol INCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Nov 1993
- Listed onNASDAQ: INCY
- Listed entityIncyte Corporation
- Exchange sectorHealth technology
- ISINUS45337C1027
- Share price$108.62 (-2.46% on the day) · 2026-10-13
- Market capitalisation$22.02B
- Price to earnings13.8
- EPS (diluted, trailing year)$7.85
- Volume (last session)2,589,566
Financials of Incyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $5.14B | $1.29B | $1.44B |
| 2024 | $4.24B | $32.6M | $169.4M |
| 2023 | $3.70B | $597.6M | $734.4M |
| 2022 | $3.39B | $340.7M | $667.4M |
| 2021 | $2.99B | $948.6M | $695.4M |
Detailed financial statements for Incyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Incyte
Incyte has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Escient Pharmaceuticals, Proteome and Vega Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Solutions for rare blood disorders are provided by Vega Therapeutics. | vega-therapeutics.com | San Francisco, United States | 2018 | Jun 2026 | $1.25B | |
Small molecule therapeutics for inflammatory diseases are developed. | escientpharma.com | San Diego, United States | 2017 | Apr 2024 | $750M | |
Novel antibody therapeutics for vitiligo treatment are developed. | villaristherapeutics.com | Cary, United States | 2019 | Oct 2022 | •••• | |
Proteomics information is provided to researchers and organizations. | proteome.com | Beverly, United States | 1995 | Dec 2000 | $77M |
Complete acquisition details for Incyte
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Incyte
7 dated milestones of Incyte across 35 years, from founding to its latest funding, stage changes and deals.
- Founded Incyte is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Proteome.
- Funding First funding round of $750.0M.
- Acquisition Acquires Villaris Therapeutics.
- Acquisition Acquires Escient Pharmaceuticals.
- Acquisition Acquires Vega Therapeutics.
Similar companies to Incyte
Incyte has 3 listed similar companies in our database, 3 of them funded. They include Moderna, BeiGene and Annexon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases |
Detailed similar companies of Incyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Incyte
The website of Incyte (incyte.com) receives about 82.2K visits a month.
- Monthly visits82.2K
▼ 13% vs previous month
Websites whose visitors overlap most with Incyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| criver.com | 100% | 224.6K | #186,811 | View details | |
| icagen.com | 100% | View details | |||
| biospace.com | 85% | 720.1K | #88,394 | View details | |
| symyx.com | 66% | View details | |||
| perkinelmer.com | 66% | 164.5K | #258,286 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Incyte
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Incyte (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Incyte
Complete news archive for Incyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Incyte
Incyte was founded in 1991 and raised its 1st funding round 22 years after it was founded.
Incyte is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Herve Hoppenot is the CEO of Incyte, as recorded in our data.
Incyte has 2,620 employees.
Annual revenue of Incyte is $5.14B as on Dec 31, 2025.
Incyte is engaged in the development of biopharmaceutical solutions targeting unmet medical needs. The company operates in the healthcare sector, with a focus on oncology and dermatology. Innovative treatments and therapies are developed to address complex health challenges. Partnerships and scientific excellence are emphasized to drive patient-centered solutions globally.
Incyte offers Oncology Solutions and Dermatology Solutions.
Yes, Incyte is publicly traded on NASDAQ under the ticker symbol INCY.
Incyte has made 4 acquisitions, including Escient Pharmaceuticals, Proteome, and Vega Therapeutics.
Incyte operates through Incyte.